Preview

Rational Pharmacotherapy in Cardiology

Advanced search

Heterogeneity of abdominal obesity in patients with cardiovascular diseases

https://doi.org/10.20996/1819-6446-2021-12-17

Full Text:

Abstract

Aim: To assess the content of visceral adipose tissue (VAT) in patients with abdominal obesity and its relationship with metabolic disorders.

Material and methods. Patients with abdominal obesity (n=107) were included in the study. All participants had an assessment of anthropometric parameters (height, weight), calculation of body mass index (BMI), proportion of total adipose tissue and VAT (bioimpedance analyzer), high-density lipoprotein cholesterol (HDL-c) levels, triglycerides, fasting blood glucose, epicardial thickness adipose tissue (two-dimensional echocardiography).

Results. The median share of VAT (bioimpedance method) was 13%. Patients with abdominal obesity are divided by VAT into 2 groups: ≥14% or ≤13%. Patients with VAT≥14% had significantly higher levels of triglycerides (1.76 [1.27; 2.38] mmol / L) and glucose (6.33 [5.78; 7.87] mmol / L), and below HDL-c levels (0.95 [0.85; 1.21] mmol / L) compared with patients with VAT≤13% (1.32 [1.02; 1.50], 5.59 [5, 11; 6.16] and 1.31 [1.07; 1.58] mmol / L, respectively; p<0.001 for all three comparisons). A significant correlation was found between VAT and triglyceride, glucose and HDL-c levels (r=0.40; r=0.40; r=-0.31, respectively; p<0.001).

Conclusion. Persons with abdominal obesity are heterogeneous in the proportion of VAT. The proportion of VAT above the median is associated with metabolic disorders that are significant for the development and progression of atherosclerosis. An increase in BMI in obese individuals is not associated with an increase in VAT and an increase in the severity of metabolic disorders.

About the Authors

S. V. Miklishanskaya
Russian Medical Academy of Continuous Professional Education
Russian Federation

Sofia V. Miklishanskaya.

Moscow.

eLibrary SPIN 2843-1855



L. V. Solomasova
Russian Medical Academy of Continuous Professional Education
Russian Federation

Lilia V. Solomasova.

Moscow.



A. A. Orlovsky
National Medical Research Center of Cardiology
Russian Federation

Alexey A. Orlovsky.

Moscow.

eLibrary SPIN 9976-1620



S. N. Nasonova
National Medical Research Center of Cardiology
Russian Federation

Svetlana N. Nasonova.

Moscow.

eLibrary SPIN 5423-0041



N. A. Mazur
Russian Medical Academy of Continuous Professional Education
Russian Federation

Nikolai A. Mazur.

Moscow.

eLibrary SPIN 2391-0976



References

1. Powell-Wiley Т, Poirier P, Burke L, et al. Obesity and Cardiovascular Disease: A Scientific Statement From the American Heart Association. Circulation. 2021;143(21):e984-1010. DOI:10.1161/CIR.0000000000000973.

2. Neeland IJ, Poirier P, Després JP. Cardiovascular and Metabolic Heterogeneity of Obesity: Clinical Challenges and Implications for Management. Circulation. 2018;137(13):1391-406. DOI:10.1161/CIR-CULATIONAHA.117.029617.

3. Neeland IJ, Ross R, Després JP, et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. Lancet Diabetes Endocrinol. 2019;7(9):715-25. DOI:10.1016/S2213-8587(19)30084-1.

4. Omura-Ohata Y, Son C, Makino H, et. al. Efficacy of visceral fat estimation by dual bioelectrical impedance analysis in detecting cardiovascular risk factors in patients with type 2 diabetes. Cardiovasc Diabetol. 2019;18(1):137. DOI:10.1186/s12933-019-0941-y.

5. Okorokov PL, Vasyukova OV, Vorontsov AV. The methods for the characteristic of adipose tissue in the organism and their clinical significance. Problems of Endocrinology 2014;60(3):53-8 (In Russ.) DOI:10.14341/probl201460353-58.

6. Body composition analyzer/body fat analyzer and calorie tracker. Section 6.1 Stayhealthy BC1 and Stayhealthy/Fitness Expert BC2, Body composition analyzer 510K submission [cited 2020 Jun 20]. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf5/K052522.pdf.

7. Romero-Corral A, Somers VK, Sierra-Johnson J, et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J. 2010;31(6):737-46. DOI:10.1093/eurheartj/ehp487.

8. Jung CH, Lee WJ, Song K. Metabolically healthy obesity: a friend or foe? Korean J Intern Med. 2017;32(4):611-21. DOI:10.3904/kjim.2016.259.

9. Dhana K, Koolhaas CM, van Rossum E, et al. Metabolically Healthy Obesity and the Risk of Cardiovascular Disease in the Elderly Population. PLoS One. 2016;11(4):e0154273. DOI:10.1371/journal.pone.0154273.

10. Alberti KG, Eckel RH, Grundy SM, et al. Harmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of Obesity. Circulation. 2009;120(16):1640-5. DOI:10.1161/CIRCULATIONAHA.109.192644.

11. Fruh SM. Obesity: Risk factors, complications, and strategies for sustainable long-term weight management. J Am Assoc Nurse Pract. 2017;29(S1):S3-S14. DOI:10.1002/2327-6924.12510.

12. Ozhan H, Alemdar R, Caglar O, et al. MELEN Investigators. Performance of bioelectrical impedance analysis in the diagnosis of metabolic syndrome. J Investig Med. 2012;60(3):587-91. DOI:10.2310/JIM.0b013e318244e2d9.

13. Rodríguez AS, Soidán JG, Gómez JA, et al. Metabolic syndrome and visceral fat in women with cardiovascular risk factor. Nutr Hosp. 2017;34(4):863-8. DOI:10.20960/nh.1085.

14. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002;106(25):3143-421. DOI:10.1161/circ.106.25.3143.

15. Grundy SM, Cleeman JI, Daniels SR, et al. Diagnosis and management of the metabolic syndrome: an American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation. 2005;112(17):2735-52. DOI:10.1161/CIRCULATIONAHA.105.169404.

16. Iacobellis G, Assael F, Ribaudo MC, et al. Epicardial fat from echocardiography: a new method for visceral adipose tissue prediction. Obes Res. 2003;11(2):304-10. DOI:10.1038/oby.2003.45.

17. Oliverosa E, Somersa VK, Sochor O, et al. The Concept of Normal Weight Obesity. Prog Cardiovasc Dis. 2014;56(4):4260-33. DOI:10.1016/j.pcad.2013.10.003.

18. Tchernof A, Després JP. Pathophysiology of Human Visceral Obesity: An Update. Physiol Rev. 2013;93(1):359-404. DOI:10.1152/physrev.00033.2011.

19. Miklishanskaya SV, Zolozova EA, Safiullina AA, Mazur NA. Visceral obesity in patients with different body mass indices. Therapist. 2020;(8):66-70 (In Russ.) DOI:10.26295/OS.2020.19.39.011.

20. Miklishanskaya SV, Saidova MA, Orlovsky AA, et al. Differences in the accumulation of visceral and epicardial adipose tissue in patients with and without coronary heart disease. Russian Medical Journal. 2021;(2):13-7 (In Russ.)

21. Miklishanskaya SV, Zolozova EA, Orlovsky AA, et al. Substantiation of the need to create a new classification of obesity. Therapist. 2021;7(24):58-62 (In Russ.) DOI:10.51793/OS.2021.24.7.011.


Review

For citation:


Miklishanskaya S.V., Solomasova L.V., Orlovsky A.A., Nasonova S.N., Mazur N.A. Heterogeneity of abdominal obesity in patients with cardiovascular diseases. Rational Pharmacotherapy in Cardiology. 2021;17(6):867-872. (In Russ.) https://doi.org/10.20996/1819-6446-2021-12-17

Views: 58


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 License.


ISSN 1819-6446 (Print)
ISSN 2225-3653 (Online)